Fibroblast growth factor 21 correlates with weight loss after vertical sleeve gastrectomy in adolescents

Vertical sleeve gastrectomy (VSG) results in weight loss and increased bile acids (BA) and fibroblast growth factor 19 (FGF19) levels. FGF21 shares essential cofactors with FGF19, but its physiology early post‐VSG has not been assessed.

[1]  R. Hughes,et al.  Changes in Bile Acid Profile After Laparoscopic Sleeve Gastrectomy are Associated with Improvements in Metabolic Profile and Fatty Liver Disease , 2016, Obesity Surgery.

[2]  V. Irribarra,et al.  Bile acids synthesis decreases after laparoscopic sleeve gastrectomy. , 2016, Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery.

[3]  B. Neuschwander‐Tetri,et al.  Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial , 2015, The Lancet.

[4]  R. Seeley,et al.  The role of small heterodimer partner in nonalcoholic fatty liver disease improvement after sleeve gastrectomy in mice , 2014, Obesity.

[5]  V. Tremaroli,et al.  FXR is a molecular target for the effects of vertical sleeve gastrectomy , 2014, Nature.

[6]  C. Beglinger,et al.  Bile acids and gut peptide secretion after bariatric surgery: A 1‐year prospective randomized pilot trial , 2013, Obesity.

[7]  M. Trauner,et al.  Bile Acid-Mediated Control of Liver Triglycerides , 2013, Seminars in Liver Disease.

[8]  B. Aronow,et al.  Vertical sleeve gastrectomy reduces hepatic steatosis while increasing serum bile acids in a weight-loss-independent manner , 2013, Obesity.

[9]  M. Haluzík,et al.  Laparoscopic sleeve gastrectomy differentially affects serum concentrations of FGF‐19 and FGF‐21 in morbidly obese subjects , 2013, Obesity.

[10]  C. Beglinger,et al.  Effects of chenodeoxycholic acid on the secretion of gut peptides and fibroblast growth factors in healthy humans. , 2013, The Journal of clinical endocrinology and metabolism.

[11]  L. Kaplan,et al.  Roux-en-Y gastric bypass normalizes the blunted postprandial bile acid excursion associated with obesity , 2013, International Journal of Obesity.

[12]  C. Cicione,et al.  Emerging role of fibroblast growth factors 15/19 and 21 as metabolic integrators in the liver , 2012, Hepatology.

[13]  S. Spiegel,et al.  Conjugated bile acids activate the sphingosine‐1‐phosphate receptor 2 in primary rodent hepatocytes , 2012, Hepatology.

[14]  J. Flier,et al.  Obesity Is a Fibroblast Growth Factor 21 (FGF21)-Resistant State , 2010, Diabetes.

[15]  H. Itoh,et al.  Serum bile acid along with plasma incretins and serum high-molecular weight adiponectin levels are increased after bariatric surgery. , 2009, Metabolism: clinical and experimental.

[16]  J. Holst,et al.  Serum Bile Acids Are Higher in Humans With Prior Gastric Bypass: Potential Contribution to Improved Glucose and Lipid Metabolism , 2009, Obesity.

[17]  M. Matoulek,et al.  Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor‐21 in patients with type 2 diabetes and obesity , 2009, Clinical endocrinology.

[18]  Jason K. Kim,et al.  Fibroblast Growth Factor 21 Reverses Hepatic Steatosis, Increases Energy Expenditure, and Improves Insulin Sensitivity in Diet-Induced Obese Mice , 2009, Diabetes.

[19]  D. Moller,et al.  Fibroblast growth factor 21 corrects obesity in mice. , 2008, Endocrinology.

[20]  Feng Liu,et al.  Serum FGF21 Levels Are Increased in Obesity and Are Independently Associated With the Metabolic Syndrome in Humans , 2008, Diabetes.

[21]  S. Kliewer,et al.  Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21. , 2007, Cell metabolism.

[22]  J. Gromada,et al.  FGF-21 as a novel metabolic regulator. , 2005, The Journal of clinical investigation.

[23]  R. Soriano,et al.  Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes. , 2004, Endocrinology.

[24]  Sander M Houten,et al.  Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. , 2004, The Journal of clinical investigation.

[25]  D. French,et al.  Printed in U.S.A. Copyright © 2002 by The Endocrine Society Transgenic Mice Expressing Human Fibroblast Growth Factor-19 Display Increased Metabolic Rate and Decreased Adiposity , 2022 .

[26]  G. Mingrone,et al.  Reversibility of insulin resistance in obese diabetic patients: role of plasma lipids , 1997, Diabetologia.

[27]  R. Abramof.  Bariatric Surgery versus Intensive Medical Therapy in Obese Patients with Diabetes , 2012 .

[28]  N. Chinookoswong,et al.  Lack of overt FGF21 resistance in two mouse models of obesity and insulin resistance. , 2012, Endocrinology.

[29]  M. Yamaguchi,et al.  Effects of chemical modification of ursodeoxycholic acid on TGR5 activation. , 2011, Biological & pharmaceutical bulletin.